Exploration of baseline patient-reported side effect bother from cancer therapy.

Jessica K Roydhouse Bellinda L King-KallimanisPourab RoyChana WeinstockDanielle KrolSelena R DanielsDaniel L SuzmanJulia A BeaverPaul G Kluetz

Published in: Clinical trials (London, England) (2020)

Patients may enter trials already reporting some bother from side effects. This can make interpretation of results with respect to the investigational agent under study challenging. Patients may skip an item evaluating side effect bother at baseline, suggesting some difficulty with interpretation of what is being asked. Further study of the wording and utility of a baseline side effect bother assessment is warranted.

Keyphrases

patient reported
end stage renal disease
ejection fraction
newly diagnosed
chronic kidney disease
randomized controlled trial
clinical trial
patient reported outcomes
study protocol